课题基金 / 基金详情

PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C

PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C
PHI-0241-蛋白酶体抑制剂 PS-341 的 I/II 期临床试验
批准号:
7731382
负责人:
Jeffrey A Sosman
金额:
$0.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-09-16

项目摘要

项目成果

Jeffrey A Sosman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific aims: define the optimal doses of temozolomide in combination with PS-341 based upon the optimal biologic dose and the maximum tolerated dose. describe any clinical antitumor activity observed in the Phase I trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
  • 批准号:
    8142146
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2010
  • 负责人:
    Jeffrey A Sosman
  • 依托单位:
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
  • 批准号:
    7771855
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2010
  • 负责人:
    Jeffrey A Sosman
  • 依托单位:
PHI-0241- A PHASE I/II CLINICAL TRIAL OF PS-341, A PROTEASOME INHIBITOR, IN C
  • 批准号:
    7605557
  • 项目类别:
  • 资助金额:
    $0.8万
  • 财政年份:
    2006
  • 负责人:
    Jeffrey A Sosman
  • 依托单位:
海外基金